France's decision to reimburse two anti-obesity drugs introduces complex cost-benefit calculations for the national health insurance systemExecutive summary: France started reimbursing the anti-obesity injections Wegovy and Mounjaro on 15 June 2026. The reimbursement reflects a policy attempt to offset long-term obesity-related health costs, but it creates fiscal pressure on the insurance system. Health insurance authorities, Novo Nordisk, Eli Lilly, and patients with obesity. Ongoing negotiations on reimbursement levels and possible expansion to additional anti-obesity therapies are expected.The French health insurance began reimbursing Wegovy and Mounjaro from 15 June 2026. This move subjects the public system to a financial trade-off between drug spending and the broader costs of obesity. The initiative raises questions about the sustainability of reimbursement and may prompt adjustments in pricing or coverage policies.Connected developmentsObesity drug market competition between Novo Nordisk and Eli LillyOpen the full case file on Beyond →
Social Pulse
AI estimate · not scraped